Southeast Asset Advisors LLC Sells 11,360 Shares of Johnson & Johnson (NYSE:JNJ)

Southeast Asset Advisors LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 23.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,883 shares of the company's stock after selling 11,360 shares during the quarter. Johnson & Johnson accounts for 0.7% of Southeast Asset Advisors LLC's portfolio, making the stock its 22nd biggest holding. Southeast Asset Advisors LLC's holdings in Johnson & Johnson were worth $5,479,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. MRP Capital Investments LLC raised its holdings in shares of Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after acquiring an additional 65 shares in the last quarter. Syverson Strege & Co boosted its holdings in Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock valued at $202,000 after acquiring an additional 65 shares during the period. Werba Rubin Papier Wealth Management increased its stake in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after purchasing an additional 66 shares during the period. Denali Advisors LLC lifted its position in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after purchasing an additional 67 shares during the last quarter. Finally, Sage Mountain Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after purchasing an additional 67 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Remove Ads

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $2.99 on Friday, hitting $151.68. 3,837,614 shares of the company traded hands, compared to its average volume of 7,928,263. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The business has a 50-day simple moving average of $159.43 and a 200 day simple moving average of $155.27. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock has a market capitalization of $365.53 billion, a P/E ratio of 22.74, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 EPS. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Finally, Raymond James decreased their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $171.67.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.